Effect of dapagliflozin on anaemia in DAPA‐HF

Abstract

Aim Anaemia is common in heart failure and associated with worse outcomes. We examined the effect of dapagliflozin on correction of anaemia in patients with heart failure (HF) and reduced ejection fraction in DAPA‐HF. We also analysed the effect of dapagliflozin on outcomes, according to anaemia status at baseline. Methods and results Anaemia was defined at baseline as a haematocrit P = 0.44]. Similar findings were observed for cardiovascular death, HF hospitalization, and all‐cause mortality. Patients with resolution of anaemia had better outcomes than those in which anaemia persisted. Conclusion Patients with anaemia had worse outcomes in DAPA‐HF. Dapagliflozin corrected anaemia more often than placebo and improved outcomes, irrespective of anaemia status at baseline.